Quality ID #394 (NQF 1407): Immunizations for Adolescents
– National Quality Strategy Domain: Community/Population Health
– Meaningful Measure Area: Preventive Care

2019 COLLECTION TYPE:
MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:
Process

DESCRIPTION:
The percentage of adolescents 13 years of age who had the recommended immunizations by their 13th birthday

INSTRUCTIONS:
This measure is to be submitted a minimum of once per performance period for patients seen during the performance period. There is no diagnosis associated with this measure. Performance for this measure is not limited to the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on services provided and the measure-specific denominator coding.

This measure will be calculated with 4 performance rates:
1) Patients who had one dose of meningococcal vaccine on or between the patient’s 11th and 13th birthdays
2) Patients who had one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) on or between the patient’s 10th and 13th birthdays
3) Patients who have completed the HPV vaccine series with different dates of service on or between the patient’s 9th and 13th birthdays
4) All patients who are compliant for Meningococcal, Tdap and HPV during the specified timeframes

Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR (SUBMISSION CRITERIA FOR ALL RATES):
Adolescents who turn 13 years of age during the measurement period

DENOMINATOR NOTE: The same denominator is used for all rates.

Denominator Criteria (Eligible Cases):
Patients who turn 13 years of age during the measurement period
AND
Patient encounter during the performance period (CPT or HCPCS): 99201, 99202, 99203, 99204, 99205, 99211, 99212, 99213, 99214, 99215, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, 99337, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, G0402
AND NOT
DENOMINATOR EXCLUSIONS:
Meningococcal, Tdap and/or HPV vaccine contraindicated OR patient allergic to the meningococcal, Tdap, and/or HPV vaccine
OR
Patients who use hospice services any time during the measurement period: G9761

NUMERATOR (SUBMISSION CRITERIA 1):
Adolescents who had one dose of meningococcal vaccine on or between the patient’s 11th and 13th birthdays

Numerator Options:
Performance Met: Patient had one dose of meningococcal vaccine on or between the patient’s 11th and 13th birthdays (G9414)
OR
Performance Not Met: Patient did not have one dose of meningococcal vaccine on or between the patient’s 11th and 13th birthdays (G9415)

NUMERATOR (SUBMISSION CRITERIA 2):
Adolescents who had one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) on or between the patient’s 10th and 13th birthdays

Numerator Options:
Performance Met: Patient had one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) on or between the patient’s 10th and 13th birthdays (G9416)
OR
Performance Not Met: Patient did not have one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) on or between the patient’s 10th and 13th birthdays (G9417)

NUMERATOR (SUBMISSION CRITERIA 3):
Adolescents who had at least three HPV vaccines on or between the patient’s 9th and 13th birthdays

Numerator Options:
Performance Met: Patient had at least two HPV vaccines (with at least 146 days between the two) OR three HPV vaccines on or between the patient’s 9th and 13th birthdays (G9762)
OR
Performance Not Met: Patient did not have at least two HPV vaccines (with at least 146 days between the two) OR three HPV vaccines on or between the patient’s 9th and 13th birthdays (G9763)

NUMERATOR (SUBMISSION CRITERIA 4):
Adolescents who are numerator compliant for Rates 1, 2 and 3

RATIONALE:
Adolescent immunization rates have historically lagged behind early childhood immunization rates in the United States. In 2000, the American Academy of Pediatrics (AAP) reported that 3 million adolescents failed to receive at least one recommended vaccination. Low immunization rates among adolescents have the potential to cause outbreaks of preventable diseases and to establish reservoirs of disease in adolescents that can affect other populations including infants, the elderly, and individuals with chronic conditions. Immunization recommendations for adolescents have changed in recent years. In addition to assessing for immunizations that may have been missed, there are new vaccines targeted specifically to adolescents.
This measure follows the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) guidelines for immunizations.

**CLINICAL RECOMMENDATION STATEMENTS:**
Receiving recommended vaccinations is the best defense against vaccine-preventable diseases. However, as children get older, the protection they received from some of their childhood vaccinations begins to wear off and they need booster shots. Adolescents are also at risk for vaccine-preventable diseases (e.g., meningococcal meningitis) they are not typically vaccinated against as children.

The tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccine is given to adolescents as a booster shot to increase the protection they received in childhood vaccinations. Diphtheria, tetanus and pertussis are serious diseases that can cause life-threatening illnesses. Diphtheria can cause breathing difficulties, heart problems, nerve damage, pneumonia and even death. Tetanus can cause seizures and severe muscle spasms that can be strong enough to cause bone fractures of the spine, and causes death in 30 to 40 percent of cases. Pertussis can cause severe coughing spells that can interfere with breathing, as well as pneumonia, long-lasting bronchitis, seizures, brain damage and death.

Meningococcal disease occurs when the protective membranes covering the brain and spinal cord become infected and swell, and can cause serious complications, such as brain damage, hearing loss or learning disabilities.

Meningococcal disease is caused by the bacterium Neisseria meningitides, or meningococcus, and is the leading cause of bacterial meningitis in the United States (U.S.).

A meningococcal infection can spread quickly, killing an otherwise healthy adolescent in 48 hours. Although not all cases of meningococcal disease progress into meningitis, 15 percent of the cases that do progress, result in death.

Each year, many adolescents miss their recommended vaccinations, leaving them needlessly vulnerable to disease, suffering and death.

Vaccine-preventable diseases are expensive for society as a whole, costing more than $10 billion in direct medical costs and indirect societal costs.

In 2012, pertussis outbreaks were reported in a majority of states, with more than 32,000 cases and 16 deaths.

Outbreaks can occur in workplaces, schools and homes, and can result in physical, economic and social costs.

Bacterial meningitis remains a major global health threat, with an estimated 500,000 cases reported worldwide each year, accounting for at least 50,000 deaths. According to preliminary data, meningitis was responsible for 606 deaths in the U.S. in 2011.

Vaccines are a safe and effective way to protect adolescents against potentially deadly diseases and help them develop into healthy adults. Vaccines can protect their family and their community as well.

**COPYRIGHT:**
The measures and specifications were developed by and are owned by the National Committee for Quality Assurance (“NCQA”). NCQA holds a copyright in the measures and specifications and may rescind or alter these measures and specifications at any time. Users of the measures and specifications shall not have the right to alter, enhance or otherwise modify the measures and specifications, and shall not disassemble, recompile or reverse engineer the measures and specifications. Anyone desiring to use or reproduce the materials without modification for a non-commercial purpose may do so without obtaining any approval from NCQA. All commercial uses or requests for alteration of the measures and specifications must be approved by NCQA and are subject to a license at the discretion of NCQA.

The measures and specifications are not clinical guidelines, do not establish a standard of medical care and have not been tested for all potential applications. The measures and specifications are provided “as is” without warranty of any
kind. NCQA makes no representations, warranties or endorsements about the quality of any product, test or protocol identified as numerator compliant or otherwise identified as meeting the requirements of a measure or specification. NCQA also makes no representations, warranties or endorsements about the quality of any organization or clinician who uses or reports performance measures. NCQA has no liability to anyone who relies on measures and specifications or data reflective of performance under such measures and specifications. ©2004-2018 National Committee for Quality Assurance, all rights reserved.

Performance measures developed by NCQA for CMS may look different from the measures solely created and owned by NCQA.

Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measures specifications.
2019 Registry Flow for Quality ID #394 NQF 1407: Immunization for Adolescents

Submission Criteria One

Multiple Performance Rates

Denominator

Start

Patients Who Turn 13 Years of Age During the Measurement Period

Yes

Patient Had One Dose of Meningococcal Vaccine On or Between the Patient's 11th and 13th Birthdays

Yes

Data Completeness Met + Performance Met
GM14 or Equivalent (50 Patients)

No

Patient Did Not Have One Dose of Meningococcal Vaccine On or Between the Patient's 11th and 13th Birthdays

Yes

Data Completeness Met + Performance Not Met
GM15 or Equivalent (20 Patients)

No

Data Completeness Not Met
Quality Data Code or Equivalent Not Submitted (10 Patients)

No

Meningococcal, Tet and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tet, and/or HPV Vaccine

Yes

Denominator Exclusions

No

Encounter as Listed in Denominator (1/1/2010 thru 12/31/2019)

Yes

Patients Who Used Hospice Services Any Time During the Measurement Period, G279 for Equivalent

No

Include in Eligible Population/Denominator (60 Patients)

No

Not Included in Eligible Population/Denominator

Numerator

Start

This measure will be calculated with 4 performance rates.

*See the posted Measure Specification for specific coding and instructions to submit this measure.

**It is anticipated for registry submission that for every performance rate, a data completeness will be submitted. CMS will determine or use the overall data completeness and performance rates.

NOTE: Submission Frequency: Patient - process
This measure will be calculated with 4 performance rates
*See the posted Measure Specification for specific coding and instructions to submit this measure.
**It is anticipated for registry submission that for every performance rate, a data completeness will be submitted. CMS will determine or use the overall data completeness and performance rate.
NOTE: Submission Frequency: Patient - process
2019 Registry Flow for Quality ID #394 NQF 1407: Immunization for Adolescents Submission Criteria Three

Multiple Performance Rates

Start

Denominator

Patients Who Turn 13 Years of Age During the Measurement Period

No

Not Included in Eligible Population/Denominator

Encounter as Listed in Denominator* (1/1/2019 thru 12/31/2019)

Yes

Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap, and/or HPV Vaccine

Yes

Include in Eligible Population/Denominator (60 Patients)

No

Denominator Exclusions

Patients Who Use Hospice Services Any Time During the Measurement Period G9791 or Equivalent

Yes

Numerator

Patient Had at Least Two HPV Vaccines (With at Least 148 Days Between the Two) OR Three HPV Vaccines On or Between the Patient's 9th and 13th Birthdays

Data Completeness Met + Performance Met G9762 or Equivalent (59 Patients)

Yes

No

Patient Did Not Have at Least Two HPV Vaccines (With at Least 148 Days Between the Two) OR Three HPV Vaccines On or Between the Patient's 9th and 13th Birthdays

Data Completeness Met + Performance Not Met G9763 or Equivalent (10 Patients)

Data Completeness Not Met Quality-Data Code or Equivalent Not Submitted (10 Patients)

*See the posted Measure Specification for specific coding and instructions to submit this measure.

NOTE: Submission Frequency: Patient - process
2019 Clinical Quality Measure Flow for Quality ID #394 NQF 1407: Immunization for Adolescents
Submission Criteria Four
Multiple Performance Rates

**Start**

**Denominator**
- Patients Who Turn 13 Years of Age During the Measurement Period
  - Yes
    - Encounter as Listed in Denominator* (1/1/2019 thru 12/31/2019)
      - No
        - Not Included in Eligible Population/Denominator
      - Yes
        - Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine
          - Yes
            - "Data Completeness Met + Performance Met G0414, G0415, and G0762 or Equivalent (40 Patients)"
          - No
            - "Data Completeness Met + Performance Not Met Any combination that excludes Performance Not Met Code G0415, G0417, G0762 or Equivalent" (20 Patients)
  - No
    - Denominator Exclusions
      - Yes
        - Patients Who Use Hospice Services Any Time During the Measurement Period G3701 or Equivalent
          - No
            - "Data Completeness Met Not Met Quality Data Code or Equivalent Not Submitted (20 Patients)"
      - No
        - Include in Eligible Population/Denominator (80 Patients)

**Numerator**
- Adolescents Who Are Numerator Compliant for Rules 1, 2, and 3.
  - Yes
    - "Data Completeness Met + Performance Met G0414, G0415, and G0762 or Equivalent (40 Patients)"
  - No
    - Adolescents Who Are Not Numerator Compliant for Rules 1, 2, and 3.
      - Yes
        - "Data Completeness Met Not Met Any combination that excludes Performance Not Met Code G0415, G0417, G0762 or Equivalent" (20 Patients)
      - No
        - "Data Completeness Met Not Met Quality Data Code or Equivalent Not Submitted (20 Patients)"

This measure will be calculated with 4 performance rates.
*See the posted Measure Specification for specific coding and instructions to submit this measure.
**It is anticipated for registry submission that for every performance rate, a data completeness will be submitted. CMS will determine or use the overall data completeness and performance rate.
***To satisfy Data Completeness for Submission Criteria 4, the registry must ensure that the eligible clinician submits Submission Criteria One, Two, and Three. In order to meet performance on this measure, Submission Criteria One, Two, and Three must submit G0414, G0415, and G0762.

NOTE: Submission Frequency: Patient - process.
2019 Registry Flow for Quality ID #394 NQF 1407: Immunization for Adolescents

Multiple Performance Rates

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate 1**

Data Completeness:

\[
\text{Performance Met (a² = 50 patients) + Performance Not Met (c² = 20 patients) = 70 patients = 87.50%}
\]

\[
\text{Eligible Population / Denominator (d² = 80 patients) = 86 patients}
\]

Performance Rate:

\[
\text{Performance Met (a² = 50 patients) = 50 patients = 71.43%}
\]

Data Completeness Numerator (70 patients) = 70 patients

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate 2**

Data Completeness:

\[
\text{Performance Met (a³ = 60 patients) + Performance Not Met (c³ = 10 patients) = 70 patients = 87.50%}
\]

\[
\text{Eligible Population / Denominator (d³ = 80 patients) = 80 patients}
\]

Performance Rate:

\[
\text{Performance Met (a³ = 60 patients) = 60 patients = 85.71%}
\]

Data Completeness Numerator (70 patients) = 70 patients

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate 3**

Data Completeness:

\[
\text{Performance Met (a⁴ = 60 patients) + Performance Not Met (c⁴ = 10 patients) = 70 patients = 87.50%}
\]

\[
\text{Eligible Population / Denominator (d⁴ = 80 patients) = 80 patients}
\]

Performance Rate:

\[
\text{Performance Met (a⁴ = 60 patients) = 60 patients = 85.71%}
\]

Data Completeness Numerator (70 patients) = 70 patients

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate 4**

Data Completeness:

\[
\text{Performance Met (a⁵ = 40 patients) + Performance Not Met (c⁵ = 20 patients) = 60 patients = 75.00%}
\]

\[
\text{Eligible Population / Denominator (d⁵ = 80 patients) = 80 patients}
\]

Performance Rate:

\[
\text{Performance Met (a⁵ = 40 patients) = 40 patients = 66.67%}
\]

Data Completeness Numerator (60 patients) = 60 patients

---

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Patient 6</th>
<th>Patient 7</th>
<th>Patient 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met (a¹)</td>
<td>Met (a¹)</td>
<td>Met (a¹)</td>
<td>Met (a¹)</td>
<td>Met (a¹)</td>
<td>Not Met (c¹)</td>
<td>Not Met (c¹)</td>
<td>Not Reported</td>
</tr>
<tr>
<td>Met (a²)</td>
<td>Met (a²)</td>
<td>Met (a²)</td>
<td>Met (a²)</td>
<td>Met (a²)</td>
<td>Met (a²)</td>
<td>Not Met (c²)</td>
<td>Met (a²)</td>
</tr>
<tr>
<td>Met (a³)</td>
<td>Not Reported</td>
<td>Met (a³)</td>
<td>Met (a³)</td>
<td>Met (a³)</td>
<td>Met (a³)</td>
<td>Not Met (c³)</td>
<td>Met (a³)</td>
</tr>
<tr>
<td>Met (a⁴)</td>
<td>Not Reported</td>
<td>Met (a⁴)</td>
<td>Met (a⁴)</td>
<td>Met (a⁴)</td>
<td>Met (a⁴)</td>
<td>Not Met (c⁴)</td>
<td>Not Met (c⁴)</td>
</tr>
</tbody>
</table>

---

*See the posted Measure Specification for specific coding and instructions to submit this measure.

**It is anticipated for registry submission that for every performance rate, a data completeness will be submitted. CMS will determine or use the overall data completeness and performance rate.

NOTE: Submission Frequency: Patient – process

CPT only copyright 2018 American Medical Association. All rights reserved.
2019 Clinical Quality Measure Flow Narrative for Quality ID #394 NQF 1407:
Immunization for Adolescents

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This measure includes 4 performance rates for submission.

**SUBMISSION Criteria 1:**

1. Start with Denominator

2. Check Patient Age:
   a. If Patients Who Turn 13 Years of Age During the Measurement Period equals No, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Turn 13 Years of Age During the Measurement Period equals Yes, proceed to check Encounter Performed.

3. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine.

4. Check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine:
   a. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals No, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period.

5. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d1 equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Patient Had One Dose of Meningococcal Vaccine On or Between the Patient’s 11th and 13th Birthdays:
   a. If Patient had One Dose of Meningococcal Vaccine On or Between the Patient’s 11th and 13th Birthdays equals Yes, include in Data Completeness Met and Performance Met.
b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a\(^1\) equals 50 patients in the Sample Calculation.

c. If Patient Had One Dose of Meningococcal Vaccine On or Between the Patient’s 11th and 13th Birthdays equals No, proceed to check Patient Did Not Have One Dose of Meningococcal Vaccine On or Between the Patient’s 11\(^{th}\) and 13\(^{th}\) Birthdays.

9. Check Patient Did Not Have One Dose of Meningococcal Vaccine On or Between the Patient’s 11\(^{th}\) and 13\(^{th}\) Birthdays:

   a. If Patient Did Not Have One Dose of Meningococcal Vaccine on or Between the Patient’s 11\(^{th}\) and 13\(^{th}\) Birthday equals Yes, include in the Data Completeness Met and Performance Not Met.

   b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness Rate in the Sample Calculation listed at the end of this document. Letter c\(^1\) equals 20 patients in the Sample Calculation.

   c. If Patient Did Not Have One Dose of Meningococcal Vaccine On or Between the Patient’s 11\(^{th}\) and 13\(^{th}\) Birthdays equals No, proceed to check Data Completeness Not Met.

10. Check Data Completeness Not Met:

   a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

---

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate**

<table>
<thead>
<tr>
<th>Performance Met (a^1 = 50) patients + Performance Not Met (c^1 = 20) patients</th>
<th>70 patients = 87.50%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligible Population / Denominator (d = 80) patients</td>
<td>80 patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Performance Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Met (a^1 = 50) patients</td>
</tr>
<tr>
<td>Data Completeness Numerator (70) patients</td>
</tr>
</tbody>
</table>

---
2019 Clinical Quality Measure Flow Narrative for Quality ID #394 NQF 1407:
Immunization for Adolescents

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This measure includes 4 performance rates for submission.

SUBMISSION Criteria 2:

1. Start with Denominator

2. Check Patient Age:
   a. If Patient Age Who Turns 13 Years of Age During the Measurement Period equals No, do not include in Eligible Population. Stop Processing.
   b. If Patient Age Who Turns 13 Years of Age During the Measurement Period equals Yes, proceed to check Encounter Performed.

3. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine.

4. Check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine:
   a. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals No, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period.

5. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter \( d^2 \) equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Patient Had One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays:
   a. If Patient Had One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays equals Yes, include in Data Completeness Met and Performance Met.
b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter $a^2$ equals 60 patients in the Sample Calculation.

c. If Patient Had One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthday equals No, proceed to check Patient Did Not have One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays.

9. Check Patient Did Not have One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays:

a. If Patient Did Not have One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays equals Yes, include in the Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter $c^2$ equals 10 patients in the Sample Calculation.

c. If Patient Did Not Have One Tetanus, Diphtheria Toxoids and Acellular Pertussis Vaccine (Tdap) On or Between the Patient’s 10th and 13th Birthdays equals No, proceed to check Data Completeness Not Met.

10. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

<table>
<thead>
<tr>
<th>Sample Calculations: Data Completeness and Performance Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Completeness =</td>
</tr>
<tr>
<td>Performance Met ($a^2 = 60$ patients) + Performance Not Met ($c^2 = 10$ patients) = 70 patients = $87.50%$</td>
</tr>
<tr>
<td>Eligible Population / Denominator ($d^2 = 80$ patients) = 80 patients</td>
</tr>
</tbody>
</table>

Performance Rate:

<table>
<thead>
<tr>
<th>Performance Rate =</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Met ($a^2 = 60$ patients) = 60 patients = $85.71%$</td>
</tr>
</tbody>
</table>

Data Completeness Numerator (70 patients) = 70 patients
2019 Clinical Quality Measure Flow Narrative for Quality Id#394 NQF 1407: Immunization for Adolescents

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This measure includes 4 performance rates for submission.

**SUBMISSION Criteria 3:**

1. Start with Denominator

2. Check Patient Age:
   a. If Patients Who Turn 13 Years of Age During the Measurement Period equals No, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Turn 13 Years of Age During the Measurement Period equals Yes, proceed to check Encounter Performed.

3. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine.

4. Check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine:
   a. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals No, proceed to check Hospice Services for Patient Starts Any Time During the Measurement Period.

5. Check Hospice Services for Patient Starts Any Time During the Measurement Period:
   a. If Hospice Services for Patient Starts Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Hospice Services for Patient Starts Any Time During the Measurement Period equals No, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d³ equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Patient Had At Least Two HPV Vaccines (With At Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient's 9th and 13th Birthdays:
a. If Patient Had At Least Two HPV Vaccines (With At Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays equals Yes, include in Data Completeness Met and Performance Met.

b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter $a^3$ equals 60 patients in the Sample Calculation.

c. If Patient Had At Least Two HPV Vaccines (With At Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays equals No, proceed to check Patient Did Not Have at Least Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays.

9. Check Patient Did Not Have at Least Two HPV Vaccines (With At Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays:

a. If Patient Did Not Have at Least Two HPV Vacines (With at Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays equals Yes, include in the Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness Rate in the Sample Calculation listed at the end of this document. Letter $c^3$ equals 10 patients in the Sample Calculation.

c. If Patient Did Not Have at Least Two HPV Vaccines (With at Least 146 Days Between the Two) OR Three HPV Vaccines On or Between the Patient’s 9th and 13th Birthdays equals No, proceed to check Data Completeness Not Met.

10. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

---

**SAMPLE CALCULATIONS: Data Completeness and Performance Rate**

Data Completeness = 
Performance Met ($a^3 = 60$ patients) + Performance Not Met ($c^3 = 10$ patients) = 70 patients = 87.50% 
Eligible Population / Denominator ($d^2 = 80$ patients) = 80 patients

Performance Rate = 
Performance Met ($a^3 = 60$ patients) = 60 patients = 85.71% 
Data Completeness Numerator (70 patients) = 70 patients
2019 Clinical Quality Measure Flow Narrative for Quality ID#394 NQF 1407: Immunization for Adolescents

Please refer to the specific section of the specification to identify the denominator and numerator information for use in submitting this Individual Specification. This measure includes 4 performance rates for submission.

SUBMISSION Criteria 4:

1. Start with Denominator

2. Check Patient Age:
   a. If Patients Who Turns 13 Years of Age During the Measurement Period equals No, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Turns 13 Years of Age During the Measurement Period equals Yes, proceed to check Encounter Performed.

3. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine.

4. Check Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine:
   a. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Meningococcal, Tdap and/or HPV Vaccine Contraindicated or Patient Allergic to Meningococcal, Tdap and/or HPV Vaccine equals No, proceed to check Patients Who Use Hospice Services Any Time During the Measurement Period.

5. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
   a. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Population. Stop Processing.
   b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals No, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d4 equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Adolescents Who Are Numerator Compliant for Rates 1, 2, and 3:
   a. If Adolescents Who Are Numerator Compliant for Rates 1, 2, and 3 equals Yes, include in the Data Completeness Met and Performance Met.
b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a^4 equals 40 patients in the Sample Calculation.

c. If Adolescents Who Are Numerator Compliant for Rates 1, 2, and 3 equals No, proceed to check Adolescents Who Are Not Numerator Compliant for Rates 1, 2, and 3.

9. Check Adolescents Who Are Not Numerator Compliant for Rates 1, 2, and 3:

a. If Adolescents Who Are Not Numerator Compliant for Rates 1, 2, and 3 equals Yes, include in the Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c^4 equals 20 patients in the Sample Calculation.

c. If Adolescents Who Are Not Numerator Compliant for Rates 1, 2, and 3 equals No, proceed to check Data Completeness Not Met.

10. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 20 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

```
SAMPLE CALCULATIONS: Data Completeness and Performance Rate

Data Completeness =
Performance Met (a^4 = 40 patients) + Performance Not Met (c^4 = 20 patients) = 60 patients = 75.00%

Eligible Population / Denominator (d^2 = 60 patients) = 60 patients

Performance Rate =
Performance Met (a^4 = 40 patients) = 40 patients = 66.67%

Data Completeness Numerator (60 patients) = 60 patients
```